gvs 111 has been researched along with glucagon-like peptide 1 in 1 studies
| Studies (gvs 111) | Trials (gvs 111) | Recent Studies (post-2010) (gvs 111) | Studies (glucagon-like peptide 1) | Trials (glucagon-like peptide 1) | Recent Studies (post-2010) (glucagon-like peptide 1) |
|---|---|---|---|---|---|
| 91 | 2 | 31 | 9,484 | 1,208 | 6,374 |
| Protein | Taxonomy | gvs 111 (IC50) | glucagon-like peptide 1 (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gudasheva, TA; Ivanova, EA; Kapitsa, IG; Michunskaya, AM; Ostrovskaya, RU; Ozerova, IV; Seredenin, SB; Taraban, KV; Voronina, TA; Zolotov, NN | 1 |
1 other study(ies) available for gvs 111 and glucagon-like peptide 1
| Article | Year |
|---|---|
Noopept normalizes parameters of the incretin system in rats with experimental diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Insulin; Male; Pancreas; Pyrazines; Rats, Wistar; Sitagliptin Phosphate; Triazoles | 2014 |